Kornimate/medical-research-clean huggingface dataset:
extensive peritoneal lavage after curative gastrectomy for gastric cancer: a randomised controlled trial

Conditions: Gastric Cancer

Summary: this study is carried out to determine the merit and reliability of extensive intraoperative peritoneal lavage as a preventive strategy hypothesis: epl significantly improve the overall survival of patients by reducing the risk of peritoneal recurrence

gastric cancer is the second most common cause of cancer death worldwide. surgery is the mainstay treatment for cure. peritoneum is a common site of recurrence and the prognosis in patients with peritoneal recurrence is dismal. hence, prevention is essential to patient's outcomes. in patients with serosal invasion, about half experience peritoneal recurrence within first 2 years after surgery, even after curative surgery. peritoneal metastasis is caused by the implantation of free cancer cells in the peritoneal cavity exfoliated from the primary tumor before or during curative surgery. it is well known that cancer cells spillage could occur during surgery due to manipulation or even after lymph node dissection. if we can remove these free exfoliated cancer cells on the peritoneal lining, we may reduce the risk of tumor recurrence. recently, a study has demonstrated a dramatic reduction of peritoneal recurrence with extensive peritoneal lavage (epl) in patients who underwent curative resection of gastric cancer. epl was performed after the curative operation . the peritoneal cavity was washed with normal saline which is then followed by the complete aspiration of the fluid. this procedure was done 10 times using 1 liter of normal saline. the method was based on the 'limiting dilution theory' in which the method can dilute the number of free cancer cells to minimal hence reduce the risk of tumor implantation. in this study, among patients with microscopic peritoneal metastasis, peritoneal recurrence developed in 40% of patients with epl and surgery, compared to 89.7% in patients with surgery alone. epl carries minimal risk to patients. it is simple and inexpensive, and it is not time consuming. hence, it may be an effective strategy for treatment of gastric cancer.

Eligibility criteria:
inclusion criteria: * patients who have t3 (subserosal) or t4 (serosal) disease based on ct scan and intra-operative inspection with any n staging and m0 gastric cancer. * patients planned for open or laparoscopic gastrectomy. * patients undergoing gastrectomy with curative intent. * lower age limit of research subjects 21 years old and upper age limit of 80 years old. * ability to provide informed consent exclusion criteria: * patients who undergo a palliative gastrectomy. * patients who undergo a gastrectomy as emergency. * vulnerable persons under age of 21. * patients receiving neoadjuvant therapy. * patients presented with life-threatening bleeding from tumour * asa score of 4 \& 5 * patients with another primary cancer within last 5 years * patients with gross peritoneal and liver metastasis at surgery.

Keywords: extensive peritoneal lavage overall survival disease free survival peritoneal recurrence rate t3 and t4 gastric cancer
the effect of progressive relaxation exercise on pain and kinesiophobia after lumbar disc herniation surgery

Conditions: Lumbar Disc Herniation

Summary: we aimed to assess the influence of progressive muscle relaxation exercise on kinesiophobia and pain during after lumbar disc surgery using the visual analog scale (vas) and the tampa kinesiophobia scale in a prospective, randomized fashion.

lumbar disc herniation (ldh) is a common disease that is common in the society and limits the activities of individuals in daily life. pain, which is an undesirable but expected result of surgical interventions, which are used in the treatment of diseases and play an important role in increasing the health level of people, is one of the most common postoperative complaints. the pain is sometimes severe enough to impede movement and causes paravertebral muscle spasm. pain can also cause kinesiophobia, which is a factor that limits the person's physical activities. this study was conducted to determine the effect of progressive muscle relaxation exercises on kinesiophobia, which can be seen in parallel with pain in the postoperative period, on the pain level of patients after ldh surgery and on the kinesiophobia experienced in parallel. the following hypotheses (h) were tested in this study: h1. progressive muscle relaxation exercise has an effect on reducing pain after ldh surgery. h2. progressive muscle relaxation exercise has an effect on reducing kinesiophobia after ldh surgery.

Eligibility criteria:
inclusion criteria: * • the patients included in the study had lumbar microdiscectomy surgery, * patients aged 18 and over * patients should not have any problems that would prevent them from expressing their pain level correctly and from understanding the information given, * the patients do not have any psychological disorders, * the patients do not have any other acute disease that will cause pain. exclusion criteria: * • being diagnosed with a psychiatric disorder, * a complication (bleeding, hospital infection, etc.) developed in the patients before, during and after the operation within three days, * not knowing turkish.
cell free dna quantification in patients with endometriosis followed witd medical assistance to procreation

Conditions: Endometriosis; Cell Free DNA

Summary: endometriosis is a common benign disease in premenopausal women and causes chronic pelvic pain and infertility. this infertility may be due to pelvic adhesions and surgery but also because of poor oocyte quality. it is known that endometriosis is associated with an increase oxidative stress, wich induce chronic inflammation, deleterious effect for dna, proteins and can caused cellular death. ros markers found in follicular fluid or in serum are significatively higher in endometriosis women. the investigators want to dose a marker of apoptosis in infertile women and see if it's significatively higher in serum and in follicular fluid of patients with endometriosis compared to others infertility causes and if it's correlated to oocyte quality and ivf results. real time pcr will be used to dose cell free dna in serum and follicular fluid of patients undergoing ivf treatment (endometriosis and infertility due to tubal factor, male infertility or idiopathic cause). then the investigators will compare cell free dna rate with oocyte and embryo quality and with pregnancy outcomes in the different group.


Eligibility criteria:
inclusion criteria: * patients eligible medical assistance to procreation who are about to undergo ivf treatment * aged between 18 and 43 years old * and who have signed a consent form exclusion criteria: * patients who are not eligible for medical assistance to procreation, * patients who are followed for other inflammatory disease, * patients followed for premature ovarian failure or * patients with a recent story of pelvic infection

Keywords: endometriosis cell free dna oocyte quality
multicenter study of rasagiline in parkinson's disease patients using levodopa and experiencing motor fluctuations

Conditions: Parkinson's Disease

Summary: study for patients currently using levodopa/carbidopa who will be assigned to receive either rasagiline or placebo


Eligibility criteria:
inclusion criteria: men and women with idiopathic parkinson's disease whose diagnosis is confirmed by at least two of the cardinal signs (resting tremor, bradykinesia, rigidity) being present, without any other known or suspected cause of parkinsonism. subjects must experience levodopa related motor fluctuations averaging at least 2.5 hours daily in the off state. subjects must be taking optimized levodopa/carbidopa or levodopa /benserazide carbidopa/levodopa therapy (based on investigator's judgment), stable for at least 14 days prior to baseline. subjects must be receiving at least 3 daily doses of levodopa, not including a bedtime dose. selegiline must be discontinued for at least 90 days prior to baseline. subject must be age 30 or older. subjects must be willing and able to give informed consent. exclusion criteria: subjects with a clinically significant or unstable medical or surgical condition which would preclude safe and complete study participation. such conditions may include cardiovascular, pulmonary, hepatic, renal, or metabolic diseases or malignancies as determined by medical history, physical exam, laboratory tests, chest x-ray, or ecg for parkinson's disease \[e.g., pallidotomy, thalamotomy, and deep brain stimulation (dbs)\] within the 12 months preceding the baseline visit. subjects who have undergone neurosurgical transplantation are excluded regardless of when the procedure(s) was performed. no programming changes are permitted in subjects who have undergone dbs. participation in a previous clinical trial of rasagiline. concomitant therapy with mao inhibitors, reserpine, methyldopa within the past three months, or treatment with an anti-emetic or neuroleptic medication with central dopamine antagonist activity with the past six months.
long-term follow-up study of subjects who completed clinical studies 755.1100_fa, 810.1100_fa, or 1064.1100_fa

Conditions: Acne Vulgaris

Summary: this study evaluates the safety, effectiveness, and maintenance of effect of a novel topical silver particle solution (sienna 755.1100, 810.1100, or 1064.1100) used in conjunction with a laser for the treatment of acne vulgaris.


Eligibility criteria:
inclusion criteria: * subject has participated in study 755.1100_fa, 810.1100_fa, or 1064.1100_fa and fulfilled that study's exit criteria (ie, completion of the final visit \[visit 7\] of that study). * subject has followed predecessor study restrictions prior to study entry. * subject is able to provide informed consent and health insurance portability and accountability act (hipaa); minors will in addition have parent or legal guardian provide consent. * subject is willing to comply with the schedule, procedures, and restrictions of the study. exclusion criteria: * subjects who have had any treatments or conditions (eg, pregnancy or metabolic disease) that may affect assessment of the safety or efficacy since enrollment in the predecessor study.
empathy through pain control: lidocaine paracervical block for iud placements

Conditions: Contraception; Pain, Acute; Anesthesia, Local

Summary: the goal of this research study is to learn more about how different uses of a numbing medication might affect pain levels while getting an iud placed. the investigators are also studying participants opinions of their clinicians' empathy. the investigators are inviting patients who arrive at their clinic visit seeking an iud. usually, at university of california, san diego (ucsd), for patients who have never delivered a baby, clinicians use a buffered paracervical block for before iud placement. the purpose of this research study is to investigate whether a "buffered" (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) paracervical block (numbing medication given on both sides of the cervix) is effective in reducing pain during iud placement in individuals with prior c-sections, the difference between buffered and unbuffered for nulliparous patients, and whether a medicated gel reduces pain with the paracervical block.

lidocaine is a drug that has been approved by the food and drug administration (fda). sodium bicarbonate is an additive that buffers the acidity of lidocaine. the combination of the two is safe and effective as a paracervical block for pain relief in various obgyn procedures. at ucsd and other places, it is not currently standard practice for people with prior deliveries birth to receive a paracervical block prior to iud placement. participants who take part in this study, may receive an injection of buffered lidocaine (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine), an injection of unbuffered block, and/or lidocaine gel. throughout the local anesthetic and intrauterine device (iud) placement procedure, research team members will present participants with questionnaires to complete to assess participants' pain, participants' satisfaction with the procedure, and how much empathy participants feel the clinician has shown.

Eligibility criteria:
inclusion criteria: 1. ability to provide informed consent 2. women iud placement for contraception or heavy menstrual bleeding 3. ages 18-50 4. english-speaking 5. participants must not have a past medical history of substance use disorders, pain disorders, use of prescription pain medications or are found to be pregnant exclusion criteria: 1. no history of vaginal delivery 2. current use of prescription pain medication prior to procedure. over-the-counter medications such as those containing ibuprofen, aspirin, acetaminophen, or naproxen are allowed. 3. diagnosed chronic pain condition 4. current pregnancy 5. known allergic reactions to components of the local anesthetic 6. history of an iud placement 7. current substance use or history of substance use 8. known contraindications to iud, such as unexplained vaginal bleeding
the feasibility of lvhiit on inpatient stroke rehab

Conditions: Stroke; High Intensity Interval Training; Aerobic Fitness; Physical Therapy

Summary: the objective of this study is to explore the safety and feasibility of conducting low-volume, high-intensity interval training (hiit) on a total body recumbent stepper (tbrs) in persons with stroke in an inpatient rehabilitation setting.


Eligibility criteria:
inclusion criteria: * -both sexes between the age of 18-85 years at time of consent * ischemic or hemorrhagic stroke at consent. people with stroke and newly diagnosed cardiovascular complications had \>50% prevalence of recurrent stroke at 5 years. index stroke or recurrent stroke on same side as index stroke will be allowed. * exercise continuously for minimum of 30 watts for 3 minutes on the recumbent stepper to demonstrate ability to perform the exercise test or therapist confirmation/documentation of participant's ability to use the recumbent stepper. * no aerobic exercise contraindications or other safety/physical concerns during the submaximal exercise test determined by the therapy team or inpatient physicians. * able to communicate with investigators, follow 2-step command \& correctly answer consent comprehension questions exclusion criteria: * implanted pacemaker or defibrillator limiting exercise performance * reported pain that limits or interferes with activities of daily living and physical activity/exercise * acute myocardial infarction in the last 2 days * ongoing unstable angina * active endocarditis * symptomatic severe aortic stenosis * decompensated heart failure * acute pulmonary embolism, pulmonary insufficiency, or deep veinous thrombosis * acute myocarditis or pericarditis * other significant neurologic, orthopedic, or peripheral vascular conditions that would limit exercise participation * oxygen-dependent chronic obstructive pulmonary disease * neurological disease (multiple sclerosis, alzheimer's disease, parkinson's disease) * pregnancy
pediatric second influenza dose portal reminder recall

Conditions: Influenza; Respiratory Tract Infections

Summary: this trial is taking place in los angeles, ca among patients from primary care practices within the ucla health system. the study design is a parallel 2-arm trial. the parallel arms are 1) a reminder letter for the second dose of influenza vaccine (reminder messages sent via the patient portal) with a direct appointment scheduling link included in the reminder and 2) a reminder letter for the second dose of influenza vaccine, but no direct appointment scheduling link included.

this trial is taking place in los angeles, ca among patients from primary care practices within the ucla health system, using a parallel 2-arm trial. sub-optimal vaccination rates are a significant problem in the u.s., despite their effectiveness in preventing morbidity and mortality from vaccine-preventable illness. in the u.s., annual epidemics of influenza cause substantial morbidity in the u.s. with up to 40,00-80,000 deaths/year and many hospitalizations, emergency and outpatient visits, and significant costs. young children-especially those younger than 2- are at high risk of developing serious flu-related complications. children ages of 6 months to 8 years getting vaccinated for the first time with influenza vaccine should get two doses, and those who have only previously gotten one dose of influenza vaccine, should get a second dose (spaced at least 4 weeks apart). reminder/recall (r/r) messages, sent by phone, mail or other modality, can improve child vaccination rates. however, the majority of pediatric or adult primary care practices to not conduct r/r. barriers are lack of finances, personnel, and algorithms to identify eligible patients. a technological breakthrough that might overcome these barriers involves patient portals-- secure, web-based communication systems, embedded within electronic health records (ehrs), for patients and providers to communicate with each other via email and the internet. portals are increasingly used by healthcare systems. this randomized controlled trial will assess the effectiveness of reminders messages, sent to the proxy of pediatric patients ages 6 months to \<36 months of age eligible for a second dose of the influenza vaccine based on data in the ehr. patients will be randomized into one of two arms to receive 1) a reminder letter for a second dose of influenza vaccine, with a direct appointment scheduling link included in the letter or 2) a reminder letter for a second dose of influenza vaccine, without a direct appointment scheduling link included in the letter.

Eligibility criteria:
inclusion criteria: * patient within the ucla health system identified as a primary care patient per an internal algorithm * identified as being overdue for a second dose of influenza vaccine. exclusion criteria: * patient within the ucla health system not identified as a primary care patient per an internal algorithm * not due for a second dose of influenza vaccine.

Keywords: vaccination reminder recall patient portal
can hepatic-splenic elastography predict the risk of hepatocellular recurrence after radiofrequency ablation?

Conditions: HCC - Hepatocellular Carcinoma

Summary: the study aims to assess whether there is an association between hepatic and splenic elastography values and the risk of hcc recurrence after treatment with rfa

the primary objective of the study will be to assess whether there is an association between hepatic and splenic elastography values and the risk of hcc recurrence after treatment with rfa. secondary objectives, however, will be to test whether hepatic and splenic elastography values have an association with overall and hcc-related survival and with the risk of decompensation after treatment with rfa; further secondary objective will be to evaluate the association between non-invasive biochemical tests and the risk of hcc recurrence after treatment with rfa. the population will consist of hepatopathic patients with hcc who are candidates for treatment with rfa and who are referred to the coordinating center "u.o.c. of gastroenterology and digestive endoscopy" of ircss azienda ospedaliero-universitaria, policlinico di s.orsola and the participating center "u.o. of gastroenterology," azienda ospedaliero-universitaria integrata di modena.

Eligibility criteria:
inclusion criteria: * clinical-instrumental diagnosis of chronic liver disease. * indication for treatment of hcc with rfa using the barcelona clinic liver cancer (bclc staging system) classification system19; * performing hepatic or splenic elastography by transient method with fibroscan® (echosens, paris, france) or arfi method (acuson sequoia siemens). * signature of informed consent exclusion criteria: * age \< 18 years; * diagnosis of hepatocholangiocarcinoma or other hepatic focal lesions other than hepatocellular carcinoma; * previous history of liver transplantation (olt) and/or liver resection for hcc in the previous two years; * liver disease in decompensation (child-pugh c) at the time of informed consent or within three months prior to enrollment; * patients with other severe and advanced diseases that may affect short-term mortality (e.g. further non-remission neoplasms, heart failure \>nyha iii, chronic renal failure in dialysis, pulmonary diseases dependent on home oxygen therapy).
a multicenter comparative study of the recell device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries

Conditions: Burns

Summary: this is a randomized, within-patient controlled study to compare the clinical performance of the recell device with that of split-thickness meshed skin grafts for the treatment of second degree burns. the hypothesis to be supported are: 1) non-inferiority with the primary efficacy endpoint defined as recipient site wound closure at week 4 follow-up visit of the recell-treated area as compared to that of the stmsg-treated area, and 2)superiority in the healing of the recell donor site as compared to the stmsg donor site at week 1.


Eligibility criteria:
inclusion criteria: * the subject requires primary skin grafting as a result of an acute thermal burn injury * the area of the burn injury is at least 200cm2 (1% tbsa in adults) if a contiguous wound, or at least 100cm2 for each of 2 noon-contiguous wounds * the area of total burn injury is 1-20% tbsa * the burn injured area can be divided into two treatment areas ( control and treatment) with 100-320cm2 area for each treatment type * the study treatment area is a second degree burn injury * the subject is between 18-65 years of age * the subject is willing to complete all follow-up evaluations required by the study protocol * the subject is to abstain from any other treatment of the wound(s) for the duration of the study unless medically necessary * the subject agrees to abstain from enrollment in any other clinical trial for the duration of the study * the subject and/or guardian are able to read and understand instructions and give informed, voluntary, written consent * the subject is able and willing to follow the protocol requirements exclusion criteria: * the subject's burn injuries were caused by chemicals, electricity, and/or radioactive substances * the total subject burn injury is less than 1% or more than 20% tbsa * the subject has a microbiologically proven pre-existing local or systemic bacterial infection * the subject has been receiving a systemic antibiotic for more than 48 hours prior to grafting * the subject is known to have a pre-existing condition that may interfere with wound healing ( e.g. malignancy, diabetes, or autoimmune disease) * the subject is unable to follow the protocol * the subject is taking medication known to have an effect on wound healing or skin pigmentation ( e.g. systemic corticosteroids, retinoids, etc) * the subject has other concurrent conditions that in the opinion of the investigator may compromise patient safety or study objectives * the subject has a known hypersensitivity to trypsin or compound sodium lactate for irrigation (hartmann's) solution

Keywords: second degree burn injuries